Probiotic Akkermansia muciniphila alleviates acute kidney injury by protecting the intestinal barrier and modulating gut microbiota and metabolites

Abstract

Acute kidney injury (AKI) is a critical condition with limited effective therapies. Akkermansia muciniphila (A. muciniphila) is a probiotic with multiple beneficial effects, including the regulation of epithelial cell tight junctions. Since renal pathophysiology is associated with gut barrier integrity, we hypothesized that A. muciniphila may have preventive effects on AKI. We established a lipopolysaccharide (LPS)-induced AKI mouse model to evaluate the effects of A. muciniphila. Our findings showed that pretreatment with A. muciniphila significantly attenuated kidney injury, as evidenced by reduced serum creatinine and urea nitrogen levels, alongside decreased tubular necrosis and apoptosis. A. muciniphila preserved intestinal barrier integrity and induced marked shifts in gut microbial ecology and the metabolome. A. muciniphila notably induced an increase in the relative abundance of the phylum Proteobacteria while decreasing in that of the phylum Bacteroidetes. At the genus level, Prevotella, Faecalibaculum, Moraxella, and Lactobacillus were more abundant in A. muciniphila-pretreated mice. Metabolomic analysis revealed that A. muciniphila altered the gut metabolome, with changes involving pathways such as tyrosine metabolism, alanine/aspartate/glutamate homeostasis, cancer-related carbon flux, and GABAergic synaptic signaling. In conclusion, our findings indicate that A. muciniphila exerts renoprotective effects by modulating the gut-kidney axis, thereby establishing a foundation for future studies to explore the connection between gut microbiota and AKI.

Keywords

Akkermansia muciniphila / acute kidney injury / gut-kidney axis / metabolomics / gut microbiota dysbiosis

Funding

This study was funded by the National Natural Science Foundation of China (Grant No. 82470766 to H.M.), the Jiangsu Provincial Medical Key Discipline (Laboratory) Cultivation Unit (Grant No. JSDW202206 to C.X.), and the First Affiliated Hospital of Nanjing Medical University Clinical Capacity Enhancement Project (Grant No. JSPH-MC- 2022-18 to C.X.).

Additional information

The online version contains supplementary materials available at http://www.jbr-pub.org.cn/article/doi/10.7555/JBR.39.20250162.

References

[1] Ostermann M, Lumlertgul N, Jeong R, et al. Acute kidney injury[J]. Lancet, 2025, 405(10474): 241-256. doi: 10.1016/S0140-6736(24)02385-7

[2] Hamroun A, Frimat L, Laville M, et al. New insights into acute-on-chronic kidney disease in nephrology patients: The CKD-REIN study[J]. Nephrol Dial Transplant, 2022, 37(9): 1700-1709. doi: 10.1093/ndt/gfab249

[3] Knauf F, Brewer JR, Flavell RA. Immunity, microbiota and kidney disease[J]. Nat Rev Nephrol, 2019, 15(5): 263-274. doi: 10.1038/s41581-019-0118-7

[4] Fuhrman DY, Kane-Gill S, Goldstein SL, et al. Acute kidney injury epidemiology, risk factors, and outcomes in critically ill patients 16-25 years of age treated in an adult intensive care unit[J]. Ann Intensive Care, 2018, 8(1): 26. doi: 10.1186/s13613-018-0373-y

[5] Hsu CL, Schnabl B. The gut-liver axis and gut microbiota in health and liver disease[J]. Nat Rev Microbiol, 2023, 21(11): 719-733. doi: 10.1038/s41579-023-00904-3

[6] Carmody RN, Bisanz JE. Roles of the gut microbiome in weight management[J]. Nat Rev Microbiol, 2023, 21(8): 535-550. doi: 10.1038/s41579-023-00888-0

[7] Crudele L, Gadaleta RM, Cariello M, et al. Gut microbiota in the pathogenesis and therapeutic approaches of diabetes[J]. EBioMedicine, 2023, 97: 104821. doi: 10.1016/j.ebiom.2023.104821

[8] Ning L, Hong J. Gut microbiome ecological topology as next-generation biomarkers for cancer immunotherapy[J]. Cell, 2024, 187(13): 3231-3232. doi: 10.1016/j.cell.2024.04.044

[9] Krukowski H, Valkenburg S, Madella AM, et al. Gut microbiome studies in CKD: Opportunities, pitfalls and therapeutic potential[J]. Nat Rev Nephrol, 2023, 19(2): 87-101. doi: 10.1038/s41581-022-00647-z

[10] Yang J, Kim CJ, Go YS, et al. Intestinal microbiota control acute kidney injury severity by immune modulation[J]. Kidney Int, 2020, 98(4): 932-946. doi: 10.1016/j.kint.2020.04.048

[11] Shah N, Rabb H. Intestinal microbiota in experimental acute kidney injury[J]. Nephron, 2023, 147(1): 25-30. doi: 10.1159/000526265

[12] Zhu H, Cao C, Wu Z, et al. The probiotic L. casei Zhang slows the progression of acute and chronic kidney disease[J]. Cell Metab, 2021, 33(10): 1926-1942.e8. doi: 10.1016/j.cmet.2021.06.014

[13] Cani PD, Depommier C, Derrien M, et al. Akkermansia muciniphila: Paradigm for next-generation beneficial microorganisms[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(10): 625-637. doi: 10.1038/s41575-022-00631-9

[14] Han Y, Ling Q, Wu L, et al. Akkermansia muciniphila inhibits nonalcoholic steatohepatitis by orchestrating TLR2-activated γδT17 cell and macrophage polarization[J]. Gut Microbes, 2023, 15(1): 2221485. doi: 10.1080/19490976.2023.2221485

[15] Chelakkot C, Choi Y, Kim DK, et al. Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions[J]. Exp Mol Med, 2018, 50(2): e450. doi: 10.1038/emm.2017.282

[16] Martín R, Miquel S, Benevides L, et al. Functional characterization of novel Faecalibacterium prausnitzii strains isolated from healthy volunteers: A step forward in the use of F. prausnitzii as a next-generation probiotic[J]. Front Microbiol, 2017, 8: 1226. doi: 10.3389/fmicb.2017.01226

[17] Li H, Xu M, Xu X, et al. Faecalibacterium prausnitzii attenuates CKD via butyrate-renal GPR43 axis[J]. Circ Res, 2022, 131(9): e120-e134. doi: 10.1161/CIRCRESAHA.122.320184

[18] Shi Z, Li M, Zhang C, et al. Butyrate-producing Faecalibacterium prausnitzii suppresses natural killer/T-cell lymphoma by dampening the JAK-STAT pathway[J]. Gut, 2025, 74(4): 557-570. doi: 10.1136/gutjnl-2024-333530

[19] Mohtashami M, Mohamadi M, Azimi-Nezhad M, et al. Lactobacillus bulgaricus and Lactobacillus plantarum improve diabetic wound healing through modulating inflammatory factors[J]. Biotechnol Appl Biochem, 2021, 68(6): 1421-1431. doi: 10.1002/bab.2064

[20] De Filippis F, Pasolli E, Ercolini D. The food-gut axis: Lactic acid bacteria and their link to food, the gut microbiome and human health[J]. FEMS Microbiol Rev, 2020, 44(4): 454-489. doi: 10.1093/femsre/fuaa015

[21] Shah AB, Baiseitova A, Zahoor M, et al. Probiotic significance of Lactobacillus strains: A comprehensive review on health impacts, research gaps, and future prospects[J]. Gut Microbes, 2024, 16(1): 2431643. doi: 10.1080/19490976.2024.2431643

[22] Wang H, Ainiwaer A, Song Y, et al. Perturbed gut microbiome and fecal and serum metabolomes are associated with chronic kidney disease severity[J]. Microbiome, 2023, 11(1): 3. doi: 10.1186/s40168-022-01443-4

[23] Gong J, Yu J, Yin S, et al. Mesenteric adipose tissue-derived Klebsiella variicola disrupts intestinal barrier and promotes colitis by type VI secretion system[J]. Adv Sci (Weinh), 2023, 10(12): 2205272. doi: 10.1002/advs.202205272

[24] Zechner EL, Kienesberger S. Microbiota-derived small molecule genotoxins: Host interactions and ecological impact in the gut ecosystem[J]. Gut Microbes, 2024, 16(1): 2430423. doi: 10.1080/19490976.2024.2430423

[25] Krautkramer KA, Fan J, Bäckhed F. Gut microbial metabolites as multi-kingdom intermediates[J]. Nat Rev Microbiol, 2021, 19(2): 77-94. doi: 10.1038/s41579-020-0438-4

[26] Chen Q, Liang X, Wu T, et al. Integrative analysis of metabolomics and proteomics reveals amino acid metabolism disorder in sepsis[J]. J Transl Med, 2022, 20(1): 123. doi: 10.1186/s12967-022-03320-y

[27] Yamada T, Nishimura D, Inoue K, et al. Ringer's ethyl pyruvate solution attenuates hypoperfusion and renal injury after multivisceral ischemia-reperfusion in rabbits[J]. J Anesth, 2020, 34(2): 303-307. doi: 10.1007/s00540-019-02730-5

[28] Wu L, Li Q, Lu F, et al. Mitochondrial pyruvate carrier 2 mitigates acute kidney injury via sustaining mitochondrial metabolism[J]. Int J Biol Sci, 2024, 20(11): 4551-4565. doi: 10.7150/ijbs.98627

[29] Hasan S, Ghani N, Zhao X, et al. Dietary pyruvate targets cytosolic phospholipase A2 to mitigate inflammation and obesity in mice[J]. Protein Cell, 2024, 15(9): 661-685. doi: 10.1093/procel/pwae014

[30] Guillon A, Brea-Diakite D, Cezard A, et al. Host succinate inhibits influenza virus infection through succinylation and nuclear retention of the viral nucleoprotein[J]. EMBO J, 2022, 41(12): e108306. doi: 10.15252/embj.2021108306

[31] Pu M, Zhang J, Zeng Y, et al. Succinate-SUCNR1 induces renal tubular cell apoptosis[J]. Am J Physiol Cell Physiol, 2023, 324(2): C467-C476. doi: 10.1152/ajpcell.00327.2022

[32] Rogers AP, Mileto SJ, Lyras D. Impact of enteric bacterial infections at and beyond the epithelial barrier[J]. Nat Rev Microbiol, 2023, 21(4): 260-274. doi: 10.1038/s41579-022-00794-x

[33] Ghosh S, Whitley CS, Haribabu B, et al. Regulation of intestinal barrier function by microbial metabolites[J]. Cell Mol Gastroenterol Hepatol, 2021, 11(5): 1463-1482. doi: 10.1016/j.jcmgh.2021.02.007

[34] Martin-Gallausiaux C, Garcia-Weber D, Lashermes A, et al. Akkermansia muciniphila upregulates genes involved in maintaining the intestinal barrier function via ADP-heptose-dependent activation of the ALPK1/TIFA pathway[J]. Gut Microbes, 2022, 14(1): 2110639. doi: 10.1080/19490976.2022.2110639